{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:54:10Z","timestamp":1777974850567,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Singapore Translational Research","award":["NMRC\/STaR\/013\/2012"],"award-info":[{"award-number":["NMRC\/STaR\/013\/2012"]}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jcyt.2017.07.011","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T08:16:05Z","timestamp":1503648965000},"page":"1317-1324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["T-cell therapy for chronic viral hepatitis"],"prefix":"10.1016","volume":"19","author":[{"given":"Antonio","family":"Bertoletti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony Tanoto","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarene","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2017.07.011_bib0010","first-page":"1","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0015","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0020","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.79.15.9369-9380.2005","article-title":"Stealth and cunning: hepatitis B and hepatitis C viruses","volume":"79","author":"Wieland","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0025","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0030","first-page":"167","article-title":"Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction","volume":"54","author":"Kurktschiev","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0035","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0040","doi-asserted-by":"crossref","first-page":"10986","DOI":"10.1128\/JVI.01124-08","article-title":"Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire","volume":"82","author":"Tan","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0045","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/JVI.78.11.5707-5719.2004","article-title":"Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis b virus proteins in patients with chronic hepatitis B: implications for immunotherapy","volume":"78","author":"Webster","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0050","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","article-title":"The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis","volume":"181","author":"Rehermann","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0055","doi-asserted-by":"crossref","DOI":"10.1172\/JCI36587","article-title":"Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27\u2013restricted human immune response","author":"Dazert","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.27771","article-title":"Adaptation of the hepatitis B virus core protein to CD8(+) T-cell selection pressure","volume":"62","author":"Kefalakes","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0065","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1172\/JCI118191","article-title":"Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection","volume":"96","author":"Rehermann","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0070","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0080","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.4049\/jimmunol.1201613","article-title":"TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity","volume":"189","author":"Pasetto","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00010-17","article-title":"Hepatitis C virus-specific T cell receptor mRNA-engineered human T cells: impact of antigen-specificity on functional properties","volume":"91","author":"Balasiddaiah","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0090","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI116950C1","article-title":"Hepatitis B virus persistence after recovery from acute viral hepatitis","volume":"94","author":"Michalak","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coviro.2016.06.004","article-title":"Current treatments for chronic hepatitis B virus infections","volume":"18","author":"Zoulim","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/infdis\/jiu471","article-title":"Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?","volume":"211","author":"Gill","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0110","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.145.10.3442","article-title":"Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection","volume":"145","author":"Ferrari","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0115","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.174.6.1565","article-title":"Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen","volume":"174","author":"Penna","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0120","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0125","doi-asserted-by":"crossref","first-page":"10445","DOI":"10.1073\/pnas.88.23.10445","article-title":"HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen","volume":"88","author":"Bertoletti","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2013.01.006","article-title":"Chronic hepatitis B: what should be the goal for new therapies?","volume":"98","author":"Block","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0140","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis b","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0150","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti\u2013PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0155","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0160","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0165","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1172\/JCI66043","article-title":"Mobilizing monocytes to cross-present circulating viral antigen in chronic infection","volume":"123","author":"Gehring","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0170","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2014adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0175","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0264-410X(00)00461-8","article-title":"Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future","volume":"19","author":"Michel","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0180","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Mancini-Bourgine","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0185","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeli\u00e8re","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic dna immunization in chronic hepatitis b patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0200","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0205","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0210","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0215","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.celrep.2016.06.078","article-title":"Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host","volume":"16","author":"Schurich","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0220","first-page":"1","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00430-014-0377-7","article-title":"Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?","volume":"204","author":"Koh","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hep.1840180204","article-title":"Adoptive transfer of immunity to hepatitis B virus after T cell\u2013depleted allogeneic bone marrow transplantation","volume":"18","author":"Ilan","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0235","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0240","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jhep.2008.08.026","article-title":"Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft","volume":"50","author":"Loggi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0245","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0255","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0260","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0265","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0270","series-title":"Towards a commercial process for the manufacture of genetically modified T cells for therapy","author":"Kaiser","year":"2015"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0275","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/JVI.01990-10","article-title":"Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody","volume":"85","author":"Sastry","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0280","first-page":"1","article-title":"ImmTACs for targeted cancer therapy: why, what, how, and which","author":"Oates","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0285","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/mt.2016.114","article-title":"Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors","volume":"24","author":"Yang","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0290","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/hep.25875","article-title":"Targeted delivery of interferon-\u03b1 to hepatitis B virus-infected cells using T-cell receptor-like antibodies","volume":"56","author":"Ji","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0295","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI200421087","article-title":"MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs","volume":"113","author":"Sitia","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0300","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1084\/jem.178.5.1541","article-title":"Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis","volume":"178","author":"Ando","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0305","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0310","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0315","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0320","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.gastro.2012.03.041","article-title":"Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells","volume":"143","author":"Sandalova","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0330","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fimmu.2013.00057","article-title":"NK cells: a double-edged sword in chronic hepatitis B virus infection","volume":"4","author":"Maini","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0340","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4049\/jimmunol.177.1.739","article-title":"Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B","volume":"177","author":"Xu","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0345","doi-asserted-by":"crossref","first-page":"e1002061","DOI":"10.1371\/journal.ppat.1002061","article-title":"Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis","volume":"7","author":"Sitia","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0350","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/mtna.2013.43","article-title":"A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus","volume":"2","author":"Koh","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0355","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline duringpegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0365","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0370","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0375","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1092066","article-title":"Inhibition of hepatitis B virus replication by APOBEC3G","volume":"303","author":"Turelli","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0380","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbrc.2005.12.192","article-title":"Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes","volume":"341","author":"Tanaka","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0385","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1099\/vir.0.83507-0","article-title":"Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H","volume":"89","author":"K\u00f6ck","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0390","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0395","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2002-03-0791","article-title":"Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic","volume":"101","author":"Zhang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.011_bib9000","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-0037-1600522","article-title":"Clinical trial design for immune-based therapy of hepatitis B virus","volume":"37","author":"Gill","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0400","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cmi.2014.79","article-title":"The immune tolerant phase of chronic HBV infection: new perspectives on an old concept","volume":"12","author":"Bertoletti","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2017.07.011_bib0405","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","article-title":"Reasons to consider earlier treatment of chronic HBV infections","volume":"61","author":"Zoulim","year":"2012","journal-title":"Gut"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324917306564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324917306564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:33:39Z","timestamp":1761442419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324917306564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1465324917306564"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2017.07.011","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell therapy for chronic viral hepatitis","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2017.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}